Kos Gets GMP Warning Letter On Niaspan, Advicor Production
This article was originally published in The Pink Sheet Daily
Executive Summary
The quality control unit failed to investigate dissolution and content uniformity failures for the lipid-altering products, FDA says. The company was cited for similar violations in 2002.